Kabasakal L - Search Results

1

Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer.

Kınıkoğlu O, Öven BB, Çelik S, Alan Selçuk N, Beydağı G, Akçay K, Kabasakal L. Kınıkoğlu O, et al. Among authors: kabasakal l. J Clin Med. 2024 Aug 6;13(16):4585. doi: 10.3390/jcm13164585. J Clin Med. 2024. PMID: 39200727 Free PMC article.

2

Revision of the Histopathological Examination Following ⁶⁸Ga-DOTA-FAPI-04 PET/CT of a Breast Tumor Diagnosed as Invasive Ductal Carcinomatosis.

Alan Selçuk N, Akçay K, Beydağı G, Sönmez Ö, Çelik S, Öven BB, Kabasakal L. Alan Selçuk N, et al. Among authors: kabasakal l. Mol Imaging Radionucl Ther. 2024 Jun 28;33(2):134-137. doi: 10.4274/mirt.galenos.2024.89106. Mol Imaging Radionucl Ther. 2024. PMID: 38949561 Free PMC article.

3

Incorporating the [68Ga]Ga-PSMA PET/CT PRIMARY score into the selection criteria for prostate cancer patients eligible for active surveillance.

Kabasakal L, Turkay R, Onal B. Kabasakal L, et al. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1464-1466. doi: 10.1007/s00259-024-06642-9. Eur J Nucl Med Mol Imaging. 2024. PMID: 38342786 No abstract available.

4

Prediction of clinically significant prostate cancer by [⁶⁸ Ga]Ga-PSMA-11 PET/CT: a potential tool for selecting patients for active surveillance.

Akcay K, Kibar A, Sahin OE, Demirbilek M, Beydagi G, Asa S, Aghazada F, Toklu T, Selcuk NA, Onal B, Kabasakal L. Akcay K, et al. Among authors: kabasakal l. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1467-1475. doi: 10.1007/s00259-023-06556-y. Epub 2023 Dec 19. Eur J Nucl Med Mol Imaging. 2024. PMID: 38112777

5

Differentiated Thyroid Cancer in Children and Adolescents: Clinicopathological Characteristics of 32 Patients Followed up in our Pediatric Endocrinology Unit.

Cakir AD, Bucak FT, Tarcin G, Turan H, Ozcan R, Evliyaoglu O, Kabasakal L, Ercan O. Cakir AD, et al. Among authors: kabasakal l. Sisli Etfal Hastan Tip Bul. 2023 Jun 20;57(2):224-231. doi: 10.14744/SEMB.2023.09216. eCollection 2023. Sisli Etfal Hastan Tip Bul. 2023. PMID: 37899815 Free PMC article.

6

Initial Findings on the Use of [²²⁵Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors.

Demirci E, Alan Selçuk N, Beydağı G, Ocak M, Toklu T, Akçay K, Kabasakal L. Demirci E, et al. Among authors: kabasakal l. Mol Imaging Radionucl Ther. 2023 Oct 20;32(3):226-232. doi: 10.4274/mirt.galenos.2023.38258. Mol Imaging Radionucl Ther. 2023. PMID: 37870290 Free PMC article.

7

Clinical Experience with [²²⁵Ac]Ac-PSMA Treatment in Patients with [¹⁷⁷Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer.

Alan-Selcuk N, Beydagi G, Demirci E, Ocak M, Celik S, Oven BB, Toklu T, Karaaslan I, Akcay K, Sonmez O, Kabasakal L. Alan-Selcuk N, et al. Among authors: kabasakal l. J Nucl Med. 2023 Oct;64(10):1574-1580. doi: 10.2967/jnumed.123.265546. Epub 2023 Aug 24. J Nucl Med. 2023. PMID: 37620050 Free article.

8

Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT).

Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, Osborne JR, Iravani A, Koo P, Lindenberg L, Baum RP, Bozkurt MF, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen WJG, Rahbar K, Schoder H, Virgolini I, Bodei L, Fanti S, Haberkorn U, Hermann K. Kratochwil C, et al. Among authors: kabasakal l. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2830-2845. doi: 10.1007/s00259-023-06255-8. Epub 2023 May 29. Eur J Nucl Med Mol Imaging. 2023. PMID: 37246997 Free PMC article.

9

The relationship between tumor mean standard uptake value (SUVmax) in preoperative PET/computed tomography and prognostic risk groups in endometrial cancer.

Bese T, Bicer E, Tetikli Kosuk A, Akovali B, Turan H, Kabasakal L, Demirkiran F. Bese T, et al. Among authors: kabasakal l. Nucl Med Commun. 2023 Mar 1;44(3):204-211. doi: 10.1097/MNM.0000000000001654. Epub 2022 Dec 16. Nucl Med Commun. 2023. PMID: 36729416

10

Combination therapy with chitosan/siRNA nanoplexes targeting PDGF-D and PDGFR-β reveals anticancer effect in breast cancer.

Şalva E, Özbaş S, Alan S, Özkan N, Ekentok-Atıcı C, Kabasakal L, Akbuğa J. Şalva E, et al. Among authors: kabasakal l. J Gene Med. 2023 Feb;25(2):e3465. doi: 10.1002/jgm.3465. Epub 2022 Dec 11. J Gene Med. 2023. PMID: 36413571

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters